Indoco Remedies Limited has informed the Exchange regarding a press release dated April 30, 2026, titled "Indoco Remedies announces strategic transfer of its ophthalmic division to Sunways India ".
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies has approved the transfer of its ophthalmic business division to Sunways (India) Private Limited through an Agreement to Transfer Business (ATB). The transfer covers India and certain agreed territories in Africa. Financial terms of the deal were not disclosed in the press release. Indoco's Managing Director said the move is aimed at sharpening focus on other core therapeutic areas with stronger potential. Indoco is a US$ 180 million pharma company with 10 manufacturing facilities and a presence across segments like gastro-intestinal, respiratory, anti-infectives, and cardiology, while Sunways is a private pharma player focused on ophthalmology and ENT.
This is a portfolio rationalisation where Indoco exits one of its existing therapeutic segments to focus resources elsewhere, which could free up capital and management bandwidth. Since deal value has not been disclosed, the near-term stock reaction will depend on subsequent filings revealing the consideration and how the proceeds will be used.